Blog

Year in review: What Changes Did 2023 Bring Philly’s Tech Community?

December 20, 2023

This year was full of big tech moments in the Philadelphia region. Here are 14 of the most notable or impactful, from funding to anniversaries to federal recognition. Philly, it’s hard to believe another year has come and gone. But here we are. 2023 was filled with fundraising, community gatherings and interesting technology. In Philadelphia, […]

Who Built Philly Startup Leaders? Over 15 Years, These Community Members — And Many More

December 14, 2023

The Glass Breakers Ball and awards dinner was part of PSL’s event series to recognize its 15th anniversary. Here’s who got honored. When thinking about Philly Startup Leaders’ legacy, Bob Moore wants you to consider the ship of Theseus paradox. When your vessel has all new infrastructure — or your organization has all new members […]

Philly Power Moves: You Might Recognize These Names On Cherelle Parker’s Transition Team

December 11, 2023

Plus, state gov has a new chief information security officer, Exyn Technologies announced its new CEO, and more local leadership changes. With just a few weeks to go before her tenure begins, Mayor-Elect Cherelle Parker announced the members of her transition team last week. This includes a leadership team, senior advisors, a steering committee, 13 sub-committees and a transition […]

WealthMore & Emmeline Ventures Talk About Capital Markets Supporting More Inclusive Fintech Products

December 8, 2023

Mical Jeanlys-White, Founder + CEO of WealthMore, and La Keisha Landrum Pierre, Co-Founder of Emmeline Ventures, join Judy Khan Shaw on #NYSEFloorTalk to talk about the vision for WealthMore and how capital markets can support more inclusive fintech products. The New York Stock Exchange is an American stock exchange in the Financial District of Lower […]

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

December 7, 2023

Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). For the initiation of a first-in-human Phase 1 clinical trial to evaluate the Company’s lead candidate, VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma. “The […]